AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24499609
Drug: SBIRT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SBIRT intervention for low or medium risk offenders, including brief intervention and referral to community treatment for high risk offenders.
Trial: 22031659
Drug: Low-dose plant-derived
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose plant-derived (n-3) fatty acids (2.2 g/d α-linolenic acid)
Trial: 22031659
Drug: High-dose plant-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose plant-derived (n-3) fatty acids (6.6 g/d α-linolenic acid)
Trial: 22031659
Drug: Low-dose marine-derived
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose marine-derived (n-3) fatty acids (1.2 g/d EPA and DHA)
Trial: 22031659
Drug: High-dose marine-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose marine-derived (n-3) fatty acids (3.6 g/d EPA and DHA)
Trial: 18652090
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment followed by adenotonsillectomy
Trial: 18652090
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (adenotonsillectomy and orthodontic expansion)
Trial: 16410460
Drug: rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (4 mg BID)
Trial: 12612145
Drug: Diet A
RxNorm normalized name: Diet Aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet A (24 mg Met/(kg. d) and no Cys)
Trial: 12612145
Drug: Diet B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet B (13 mg Met/(kg. d) and 11 mg Cys/(kg. d))
Trial: 12612145
Drug: Diet C
RxNorm normalized name: Diet Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet C (5 mg Met/(kg. d) and 19 mg Cys/(kg. d))
Trial: 10905679
Drug: Ceftriaxone antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone antibiotic prophylaxis
Trial: 2853038
Drug: Melatonin 1
RxNorm normalized name: melatonin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 1 mg
Trial: 7871062
Drug: Melatonin 40
RxNorm normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 40 mg
Trial: 2514318
Drug: rt‐PA (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt‐PA (60 mg over 90 minutes i.v.)
Trial: 19405832
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (delayed treatment for 3 months)
Trial: 17078435
Drug: Electrical acupuncture
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrical acupuncture and auricular-plaster therapy
Trial: 25127090
Drug: Oral hydrocortisone
RxNorm normalized name: hydrocortisone Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydrocortisone
Trial: 14700452
Drug: Venlafaxine extended-release
RxNorm normalized name: Desvenlafaxine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine extended-release (XR)
Trial: 11207517
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg b.d. (OABC group)
Trial: 11207517
Drug: Furazolidone 200
RxNorm normalized name: furazolidone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furazolidone 200 mg b.d. (OABF group)
Trial: 7180724
Drug: Active diuretic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active diuretic therapy
Trial: 26458907
Drug: Oropharyngeal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal administration of mother's milk (0.2 mL every 2 hours for 48 hours, then every 3 hours until 32 weeks corrected-gestational age)
Trial: 26458907
Drug: Placebo (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.2 mL sterile water every 2 hours for 48 hours, then every 3 hours until 32 weeks corrected-gestational age)
Trial: 21332400
Drug: STPG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STPG treatment (4 capsules, 2g)
Trial: 19541291
Drug: Lutein, zeaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein, zeaxanthin and blackcurrant extract (LUT) supplement
Trial: 9608790
Drug: Bupivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine + lidocaine (30 mg of bupivacaine plus 240 mg of lidocaine)
Trial: 9608790
Drug: Lidocaine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (300 mg)
Trial: 27541827
Drug: 6 monoclonal
RxNorm normalized name: HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY (PF-04236921)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 monoclonal antibodies (SP142, E1L3N, 9A11, SP263, 22c3, and 28-8)
Trial: 26437899
Drug: Essential amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino acids (EAAs) 8 g/d
Trial: 24798153
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 500 mg/d
Trial: 20579849
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 100 mg/d
Trial: 3752418
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of birch pollen preparation (n = 11)
Trial: 24084157
Drug: Estimated albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estimated albumin excretion rate (eAER)
Trial: 11222362
Drug: Asparaginase treatment
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asparaginase treatment duration (at least 26 weeks)
Trial: 9555799
Drug: High-dose UVA1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose UVA1 phototherapy (UVA1R; 10 days, 130 J/cm2/day; n = 20)
Trial: 9555799
Drug: Topical fluocortolone
RxNorm normalized name: fluocortolone Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluocortolone (10 days, 1 x daily; n = 17)
Trial: 9555799
Drug: UVA-UVB therapy
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA-UVB therapy (10 days, 1 x daily, minimal erythema dose-dependent; n = 16)
Trial: 2903322
Drug: Tamoxifen (TM),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TM), 30 mg daily for 2 years
Trial: 6121545
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride administration in neuroleptic-treated schizophrenics
Trial: 6121545
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride administration in total schizophrenic population
Trial: 6121545
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride administration in manic patients
Trial: 28096659
Drug: Ponesimod (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponesimod (10 mg, 20 mg, and 40 mg each consecutively for 3 days)
Trial: 18540781
Drug: Olanzapine 2.5
RxNorm normalized name: olanzapine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 2.5 mg
Trial: 24700260
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (deep breaths)
Trial: 22692271
Drug: AmF/SnF2 toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmF/SnF2 toothpaste twice daily for three minutes and AmF/SnF2 mouthrinse for 30 seconds
Trial: 22692271
Drug: AmF/SnF2 toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmF/SnF2 toothpaste twice daily for three minutes
Trial: 19631850
Drug: Non-surgical endodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical endodontic treatment
Trial: 15224028
Drug: N-acetylcysteine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (100 mg/kg into cardiopulmonary bypass prime followed by infusion at 20 mg.kg(‐1).h(‐1); n = 18)
Trial: 8026205
Drug: Continuous postural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous postural therapy on an oscillating bed
Trial: 2690332
Drug: Omeprazole, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 30 mg once daily
Trial: 2690332
Drug: Cimetidine, 200
RxNorm normalized name: Cimetidine, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 200 mg t.d.s. and 400 mg at bedtime
Trial: 1015496
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of metoclopramide intravenously
Trial: 17483854
Drug: Care recipients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Care recipients take medicines that affect the central nervous system or stomach
Trial: 15454833
Drug: MSC (Avemar)
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC (Avemar) with cytotoxic drugs
Trial: 15454833
Drug: Control (cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (cytotoxic drugs without MSC)
Trial: 29462266
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg once daily for 5 days
Trial: 9803198
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for cough or bronchitis
Trial: 9803198
Drug: Empiric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric treatment for pharyngitis
Trial: 9803198
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for common cold
Trial: 3049216
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human alpha-interferon therapy (4-month duration)
Trial: 3049216
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human alpha-interferon therapy
Trial: 31326433
Drug: Glepaglutide 1
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glepaglutide 1 mg
Trial: 28482869
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (200 mg per day in 100 ml 0.9% sodium chloride)
Trial: 28482869
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous fumarate (200 mg per day)
Trial: 25501671
Drug: Brivaracetam 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 150 mg/day
Trial: 25501671
Drug: Brivaracetam 5
RxNorm normalized name: brivaracetam 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 5 mg/day
Trial: 15706200
Drug: Art therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art therapy intervention
Trial: 16490980
Drug: Topical povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical povidone-iodine (Betadine) with compression bandages
Trial: 16490980
Drug: Topical povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical povidone-iodine (Betadine) without compression bandages
Trial: 16490980
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics (amoxicillin)
Trial: 16490980
Drug: Topical povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical povidone-iodine (Betadine)
Trial: 11194245
Drug: Repaglinide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (0.5 mg)
Trial: 24365552
Drug: Generic three-drug
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic three-drug FDC formulation (3FDC)
Trial: 24365552
Drug: 3FDC reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3FDC reference formulation
Trial: 23405793
Drug: Compound Xuanju
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Xuanju Capsule plus apomorphine hydrochloride
Trial: 20461810
Drug: Ropinirole prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole prolonged release (2-24 mg/day)
Trial: 12728300
Drug: L-tryptophan infusion
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan infusion
Trial: 9061426
Drug: Irrigating fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigating fluid absorption during TURP
Trial: 9061426
Drug: Choice of
RxNorm normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice of crystalloid or colloid solution for intravenous fluid supplementation
Trial: 6360031
Drug: 10 to
RxNorm normalized name: RE-10 Topical Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 to 15 mg oral physostigmine daily
Trial: 19854793
Drug: Clonidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.5 microg/kg bolus, followed by continuous infusion at 1‐2 microg/kg/h)
Trial: 15617992
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HD-CT) using the CMA regimen (Mitoxantrone, Cyclophosphamide, Melphalan)
Trial: 8649056
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (CT)
Trial: 10362194
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and ACE inhibitors
Trial: 10362194
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors without aspirin
Trial: 10362194
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and ACE inhibitors in congestive heart failure patients
Trial: 10362194
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors without aspirin in congestive heart failure patients
Trial: 7589340
Drug: 13‐cis‐retinoic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13‐cis‐retinoic acid (10 to 60 mg/m2/daily) administered in combination with vitamin E for 3 months to 5 years
Trial: 19387807
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A - Enoxaparin 1 mg/kg x ten doses
Trial: 19387807
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B - Enoxaparin 1 mg/kg x six doses
Trial: 19387807
Drug: Protocol C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol C - Enoxaparin 0.5 mg/kg x six doses
Trial: 16965205
Drug: Concomitant psychotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant psychotropic medications (CPMs) - antidepressants
Trial: 16965205
Drug: Concomitant psychotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant psychotropic medications (CPMs) - mood stabilizers
Trial: 16965205
Drug: Concomitant psychotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant psychotropic medications (CPMs) - modafinil and trazodone
Trial: 16965205
Drug: Concomitant psychotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant psychotropic medications (CPMs) - sleeping medications
Trial: 9523960
Drug: Initial injection
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial injection into the midcarpal and distal radioulnar joints
Trial: 9523960
Drug: Initial injection
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial injection into the radiocarpal joint
Trial: 7660509
Drug: Oral face‐to‐face
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral face‐to‐face interview
Trial: 23571304
Drug: directive counseling
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: directive counseling and sound therapy using conventional sound generators
Trial: 23571304
Drug: standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care as administered in the military
Trial: 17159758
Drug: 15 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL/kg of hydroxyethyl starch 6% (Group A)
Trial: 15571637
Drug: comicronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comicronized fenofibrate 200 mg daily
Trial: 9763251
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine and smoking cessation
Trial: 26096013
Drug: Non-invasive ventilation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive ventilation during airway clearance treatments
Trial: 17720102
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=27) received dietary advice to match intake with 1.2 g of protein per kg of ideal body weight and 25 cal/kg ideal body weight.
Trial: 17720102
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (n=28) received dietary advice to match energy intake with estimated total energy expenditure, with a protein intake of 0.8 to 1.0 g/kg.
Trial: 14728998
Drug: Hormonal replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal replacement therapy (androgens)
Trial: 9833603
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 30 g L-arginine
Trial: 9833603
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 6 g L-arginine
Trial: 9833603
Drug: Oral ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ingestion of 6 g L-arginine
Trial: 7867963
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of psycho‐active medications
Trial: 7867963
Drug: Impaired orientation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired orientation, psycho‐active drug use, evidence of stroke, and impaired performance in the 'Get‐up‐and‐go' test
Trial: 561495
Drug: Dexamethasone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (12 mg per day orally for three successive days)
Trial: 24863414
Drug: Oral antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antioxidant cocktail (vitamin C, 1000 mg; vitamin E, 600 IU; alpha‐lipoic acid, 600 mg)
Trial: 24318038
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.3 g/kg for 7 days)
Trial: 18769961
Drug: 100 microg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg/day of transdermal 17beta‐estradiol for 4 weeks
Trial: 17934931
Drug: promestriene 10
RxNorm normalized name: promestriene 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promestriene 10 mg daily, by vaginal capsule, for 21 days before the operation
Trial: 17934931
Drug: TVT (Tension‐free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVT (Tension‐free Vaginal Tape) surgical procedure without pharmacological preparation
Trial: 3071615
Drug: Ceftriaxone (CTRX)
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (CTRX) 10 mg/kg
Trial: 3071615
Drug: Ceftriaxone (CTRX)
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (CTRX) 20 mg/kg
Trial: 24105750
Drug: Interferon α-2b,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon α-2b, 3 MU three times weekly for 18 months
Trial: 17364603
Drug: Transdermal Estrogens
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Estrogens
Trial: 17364603
Drug: Oral Estrogens
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Estrogens
Trial: 17364603
Drug: Transdermal Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Placebo
Trial: 9840216
Drug: Experimental sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental sustained release tablet containing dextromethorphan hydrobromide (DXP‐HBr)